Pharmacological disruption of hair follicle pigmentation by cyclophosphamide as a model for studying the melanocyte response to and recovery from cytotoxic drug damage in situ.

PubWeight™: 0.87‹?›

🔗 View Article (PMID 8752658)

Published in J Invest Dermatol on June 01, 1996


A Slominski1, R Paus, P Plonka, B Handjiski, M Maurer, A Chakraborty, M C Mihm

Author Affiliations

1: Department of Pathology and Laboratory Medicine, Albany Medical College, New York 12208, USA.

Articles by these authors

The histogenesis and biologic behavior of primary human malignant melanomas of the skin. Cancer Res (1969) 13.27

A comprehensive guide for the accurate classification of murine hair follicles in distinct hair cycle stages. J Invest Dermatol (2001) 6.12

Interleukin 21 and its receptor are involved in NK cell expansion and regulation of lymphocyte function. Nature (2000) 5.86

Sonic hedgehog signaling is essential for hair development. Curr Biol (1998) 5.58

Controls of hair follicle cycling. Physiol Rev (2001) 5.49

Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma. Cancer (1996) 4.46

EAACI/GA(2)LEN/EDF/WAO guideline: definition, classification and diagnosis of urticaria. Allergy (2009) 4.10

Lipid A mutant Salmonella with suppressed virulence and TNFalpha induction retain tumor-targeting in vivo. Nat Biotechnol (1999) 3.97

EAACI/GA(2)LEN/EDF/WAO guideline: management of urticaria. Allergy (2009) 3.86

CENP-C, an autoantigen in scleroderma, is a component of the human inner kinetochore plate. Cell (1992) 3.70

Long-term results of a multi-institutional randomized trial comparing prognostic factors and surgical results for intermediate thickness melanomas (1.0 to 4.0 mm). Intergroup Melanoma Surgical Trial. Ann Surg Oncol (2000) 3.42

The EAACI/GA(2) LEN/EDF/WAO Guideline for the definition, classification, diagnosis, and management of urticaria: the 2013 revision and update. Allergy (2014) 3.10

Requirement of Stat3 but not Stat1 activation for epidermal growth factor receptor- mediated cell growth In vitro. J Clin Invest (1998) 3.01

Noggin is a mesenchymally derived stimulator of hair-follicle induction. Nat Cell Biol (1999) 2.99

Corticotropin releasing hormone and proopiomelanocortin involvement in the cutaneous response to stress. Physiol Rev (2000) 2.98

A comprehensive guide for the recognition and classification of distinct stages of hair follicle morphogenesis. J Invest Dermatol (1999) 2.92

GLUT1: a newly discovered immunohistochemical marker for juvenile hemangiomas. Hum Pathol (2000) 2.86

Role of the clotting system in cell-mediated hypersensitivity. I. Fibrin deposition in delayed skin reactions in man. J Exp Med (1973) 2.75

Efficacy of an elective regional lymph node dissection of 1 to 4 mm thick melanomas for patients 60 years of age and younger. Ann Surg (1996) 2.68

The classification of malignant melanoma and its histologic reporting. Cancer (1973) 2.67

Nonfamilial cutaneous melanoma incidence in women associated with sun exposure before 20 years of age. Pediatrics (1989) 2.61

Atypical Spitz nevi/tumors: lack of consensus for diagnosis, discrimination from melanoma, and prediction of outcome. Hum Pathol (1999) 2.50

Common and uncommon melanocytic nevi and borderline melanomas. Semin Oncol (1975) 2.36

Melanoma in children. N Engl J Med (1995) 2.35

Benign cutaneous adnexal tumors with combined folliculosebaceous, apocrine, and eccrine differentiation. Clinicopathologic and immunohistochemical study of eight cases. Am J Dermatopathol (1996) 2.30

Interleukin-15 protects from lethal apoptosis in vivo. Nat Med (1997) 2.22

Allergic Rhinitis and its Impact on Asthma (ARIA): achievements in 10 years and future needs. J Allergy Clin Immunol (2012) 2.17

RB1 protein in normal and malignant human colorectal tissue and colon cancer cell lines. FASEB J (1993) 2.11

Home versus hospital deliveries: follow up study of matched pairs for procedures and outcome. Zurich Study Team. BMJ (1996) 2.10

Cathepsin L deficiency as molecular defect of furless: hyperproliferation of keratinocytes and pertubation of hair follicle cycling. FASEB J (2000) 2.09

Efficacy of 2-cm surgical margins for intermediate-thickness melanomas (1 to 4 mm). Results of a multi-institutional randomized surgical trial. Ann Surg (1993) 2.08

Long-term results of a prospective surgical trial comparing 2 cm vs. 4 cm excision margins for 740 patients with 1-4 mm melanomas. Ann Surg Oncol (2001) 2.06

Noggin is required for induction of the hair follicle growth phase in postnatal skin. FASEB J (2001) 1.95

Kimura's disease and angiolymphoid hyperplasia with eosinophilia: two distinct histopathological entities. J Cutan Pathol (1987) 1.92

Automatic differentiation of melanoma from melanocytic nevi with multispectral digital dermoscopy: a feasibility study. J Am Acad Dermatol (2001) 1.91

Melanogenesis is coupled to murine anagen: toward new concepts for the role of melanocytes and the regulation of melanogenesis in hair growth. J Invest Dermatol (1993) 1.88

Nonepidermal origin of malignant melanoma associated with a giant congenital nevocellular nevus. Plast Reconstr Surg (1981) 1.86

Mast cells as sentinels of innate immunity. Curr Opin Immunol (1999) 1.85

Factors responsible for differences between asymptomatic subjects and patients presenting an IgE sensitization to allergens. A GA2LEN project. Allergy (2006) 1.84

Mast cells can secrete vascular permeability factor/ vascular endothelial cell growth factor and exhibit enhanced release after immunoglobulin E-dependent upregulation of fc epsilon receptor I expression. J Exp Med (1998) 1.84

Dermal dendritic melanocytic proliferations: an update. Histopathology (2004) 1.84

Analysis of apoptosis during hair follicle regression (catagen) Am J Pathol (1997) 1.82

Narrower margins for clinical stage I malignant melanoma. N Engl J Med (1982) 1.82

Primary melanoma of the skin: recognition and management. J Am Acad Dermatol (1980) 1.82

A new immunologic marker for human Langerhans cells. N Engl J Med (1981) 1.79

Impaired mast cell-dependent natural immunity in complement C3-deficient mice. Nature (1997) 1.78

A unique microvascular phenotype shared by juvenile hemangiomas and human placenta. Arch Dermatol (2001) 1.77

Melasma: a clinical, light microscopic, ultrastructural, and immunofluorescence study. J Am Acad Dermatol (1981) 1.76

Graying: gerontobiology of the hair follicle pigmentary unit. Exp Gerontol (2001) 1.75

Basophilic leukocytes in allergic contact dermatitis. J Exp Med (1972) 1.75

Rejection of first-set skin allografts in man. the microvasculature is the critical target of the immune response. J Exp Med (1979) 1.74

Characterization of Langerhans cells by the use of monoclonal antibodies. Lab Invest (1981) 1.73

Prognostic factors for melanoma patients with lesions 0.76 - 1.69 mm in thickness. An appraisal of "thin" level IV lesions. Ann Surg (1982) 1.72

Prevalence of head and neck cancers in the north east-An institutional study. Indian J Otolaryngol Head Neck Surg (2006) 1.72

Human monocytes constitutively express membrane-bound, biologically active, and interferon-gamma-upregulated interleukin-15. Blood (1999) 1.71

Dysplastic melanocytic nevi: a reproducible histologic definition emphasizing cellular morphology. Mod Pathol (1989) 1.71

Pilomatrix carcinoma or calcifying epitheliocarcinoma of Malherbe: a case report and review of literature. Cancer (1980) 1.70

Morphology of delayed-type hypersensitivity reactions in man. II. Ultrastructural alterations affecting the microvasculature and the tissue mast cells. Lab Invest (1976) 1.70

Morphology of delayed type hypersensitivity reactions in man. I. Quantitative description of the inflammatory response. Lab Invest (1974) 1.68

Lentigo maligna and lentigo-maligna melanoma. Am J Pathol (1969) 1.68

Squamoid eccrine ductal carcinoma. Histopathology (1997) 1.67

EAACI/GA(2)LEN task force consensus report: the autologous serum skin test in urticaria. Allergy (2009) 1.65

The clinical diagnosis, classification and histogenetic concepts of the early stages of cutaneous malignant melanomas. N Engl J Med (1971) 1.65

Autologous whole blood injections to patients with chronic urticaria and a positive autologous serum skin test: a placebo-controlled trial. Dermatology (2006) 1.65

What are melanocytes really doing all day long...? Exp Dermatol (2009) 1.65

Retracted Death deflected: IL-15 inhibits TNF-alpha-mediated apoptosis in fibroblasts by TRAF2 recruitment to the IL-15Ralpha chain. FASEB J (1999) 1.60

Studies on the cellular origin of neurothekeoma: clinical, light microscopic, immunohistochemical, and ultrastructural observations. J Am Acad Dermatol (1991) 1.59

Detection of proopiomelanocortin-derived antigens in normal and pathologic human skin. J Lab Clin Med (1993) 1.58

Molecular cloning, chromosome mapping and characterization of UBQLN3 a testis-specific gene that contains an ubiquitin-like domain. Gene (2000) 1.57

How to assess disease activity in patients with chronic urticaria? Allergy (2008) 1.55

EAACI/GA2LEN/EDF guideline: definition, classification and diagnosis of urticaria. Allergy (2006) 1.55

Melanocytes as "sensory" and regulatory cells in the epidermis. J Theor Biol (1993) 1.55

Histopathologic diagnosis of dysplastic nevi: concordance among pathologists convened by the World Health Organization Melanoma Programme. Hum Pathol (1991) 1.54

Embolization of biologic glue during repair of aortic dissection. Ann Thorac Surg (1995) 1.52

How best to fight that nasty itch - from new insights into the neuroimmunological, neuroendocrine, and neurophysiological bases of pruritus to novel therapeutic approaches. Exp Dermatol (2005) 1.51

Control of murine hair follicle regression (catagen) by TGF-beta1 in vivo. FASEB J (2000) 1.48

Bullous dermatosis of hemodialysis. Ann Intern Med (1975) 1.47

Marginal zone lymphoma (low-grade B-cell lymphoma of mucosa-associated lymphoid tissue type) of skin and subcutaneous tissue: a study of 15 patients. Am J Surg Pathol (1996) 1.45

The natural break points for primary-tumor thickness in clinical Stage I melanoma. N Engl J Med (1981) 1.45

Actin-binding protein expression in benign and malignant melanocytic proliferations. Hum Pathol (1994) 1.44

Origin of cutaneous melanoma in a congenital dysplastic nevus spilus. Arch Dermatol (1990) 1.43

A soluble class II cytokine receptor, IL-22RA2, is a naturally occurring IL-22 antagonist. Proc Natl Acad Sci U S A (2001) 1.43

Early melanoma. Histologic terms. Am J Dermatopathol (1991) 1.43

Risk of first-generation H(1)-antihistamines: a GA(2)LEN position paper. Allergy (2010) 1.42

Acral lentiginous melanoma (including in situ melanoma) arising in association with naevocellular naevi. Melanoma Res (1996) 1.42

The human hair follicle immune system: cellular composition and immune privilege. Br J Dermatol (2000) 1.42

Adjuvant high-dose interferon alfa-2b in patients with high-risk melanoma. Cancer J (2000) 1.41

Failure of topical estrogen receptor agonists and antagonists to alter murine hair follicle cycling. J Invest Dermatol (1998) 1.40

Fatal recurrent subarachnoid hemorrhage after complete endovascular aneurysm occlusion. AJNR Am J Neuroradiol (2006) 1.40

Topical axitinib suppresses angiogenesis pathways induced by pulsed dye laser. Br J Dermatol (2014) 1.40

The definition and diagnostic testing of physical and cholinergic urticarias--EAACI/GA2LEN/EDF/UNEV consensus panel recommendations. Allergy (2009) 1.39

The 'melanocyte-keratin' mystery revisited: neither normal human epidermal nor hair follicle melanocytes express keratin 16 or keratin 6 in situ. Br J Dermatol (2009) 1.39

Vitiligo pathogenesis: autoimmune disease, genetic defect, excessive reactive oxygen species, calcium imbalance, or what else? Exp Dermatol (2008) 1.39

The TGF-beta2 isoform is both a required and sufficient inducer of murine hair follicle morphogenesis. Dev Biol (1999) 1.38

The role of the hairless (hr) gene in the regulation of hair follicle catagen transformation. Am J Pathol (1999) 1.38

Thoracic epidural catheterization leading to delayed transient neurological symptoms with normal imaging findings. Acta Anaesthesiol Scand (2008) 1.38